Skip to main content
S&P 5007,560.43+0.25%DOW51,673.98-0.60%NASDAQ25,326.24+0.64%BTC$77,210.00-0.82%ETH$2,285.09-0.14%GOLD$3,953.30-0.41%OIL$96.14-0.33%
Smart Investors Daily
SID Premium
NE

NASDAQ · NERV

Minerva Neurosciences, Inc.

Healthcare · Biotechnology

$2.35

Up+$0.03 (+1.08%)

Updated Nov 3, 2026, 2:14 PM

SID Score

2.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
28.95M
P/E ratio
2.79
Dividend yield
0.00%
52-week range
$1.96 – $8.80
Volume
230.65K
Avg. volume
3.01M

Price performance · NERV

NERV price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 2, 2026

NERV closed at $2.35 after 21 trading sessions, down 29.37% for the selected period.

Last close
$2.35
Period change
-29.37%
Period low
$2.20
Period high
$3.43
Daily close
View OHLC price history
NERV OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 2, 2026$2.34$2.51$2.30$2.345230.65K
Oct 30, 2026$2.23$2.32$1.96$2.32394.69K
Oct 29, 2026$2.25$2.445$2.20$2.24267.56K
Oct 28, 2026$2.23$2.27$2.12$2.21204.4K
Oct 27, 2026$2.25$2.335$2.20$2.23239.28K
Oct 26, 2026$2.30$2.35$2.18$2.20173.15K
Oct 23, 2026$2.37$2.65$2.25$2.30137.59K
Oct 22, 2026$2.39$2.50$2.37$2.40121.14K
Oct 21, 2026$2.53$2.59$2.39$2.39102.62K
Oct 20, 2026$2.33$2.59$2.32$2.53194.28K
Oct 19, 2026$2.37$2.47$2.24$2.32118.34K
Oct 16, 2026$2.42$2.47$2.30$2.3585.6K
Oct 15, 2026$2.37$2.495$2.28$2.42159.38K
Oct 14, 2026$2.51$2.565$2.31$2.35254.31K
Oct 13, 2026$2.88$3.08$2.505$2.515185.68K
Oct 12, 2026$3.18$3.23$2.87$2.8984.91K
Oct 9, 2026$3.23$3.31$3.13$3.18192.5K
Oct 8, 2026$3.25$3.365$3.13$3.22143.49K
Oct 7, 2026$3.36$3.46$3.25$3.27106.47K
Oct 6, 2026$3.38$3.49$3.28$3.43105.31K
Oct 5, 2026$3.30$3.56$3.19$3.3272.36K

Latest NERV news

The latest Smart Investors Daily articles mentioning NERV.

Stock researchCompany · Overview

NERV research

Overview

Company profile and research snapshot.

Company profile

Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$5.00
Implied upside
—
Analysts
—
NERV recent ratings
DateFirmRatingTarget
Aug 14, 2026JefferiesBuy—
Apr 15, 2026CitizensMarket Outperform—
Mar 12, 2026HC Wainwright & Co.Neutral—
Nov 6, 2025HC Wainwright & Co.Neutral—
Feb 26, 2025HC Wainwright & Co.Neutral—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 29, 2026

Minerva Neurosciences to Participate in 2026 Jefferies Global Healthcare Conference in London

BURLINGTON, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that management will participate in the 2026 Jefferies Global Healthcare Conference in London. 2026 Jefferies Global Healthcare ConferenceDates: Monday, November 16 & Tuesday, November 17, 2026 Format: Fireside chat and 1x1 meetingsFireside Chat: Monday, Novemb

Yahoo · Oct 28, 2026

Minerva Neurosciences to Host In-Person KOL Event to Discuss Roluperidone for Negative Symptoms of Schizophrenia

BURLINGTON, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that it will host an in-person and virtual event in New York on Thursday, November 12, 2026, at 10:00 AM ET featuring several key opinion leaders and company management focused on the opportunity for roluperidone in treating the negative symptoms of schizophren

Yahoo · Aug 28, 2026

Minerva Neurosciences to Participate in Two Upcoming Investor Conferences

BURLINGTON, Mass., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that management will participate in two upcoming investor conferences. Wells Fargo Healthcare ConferenceDate: Tuesday, September 8Format: 1x1 meetingsLocation: New York, NY 2026 Cantor Global Healthcare ConferenceDate: Wednesday, September 9Format: Fireside cha

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By